AHRQ cost-effectiveness agenda
This article was originally published in The Gray Sheet
Executive Summary
Initial priority list should be directed toward prescription drug comparative clinical effectiveness in expectation of the Medicare Rx benefit, according to an 1April 23 Federal Register notice. The agency notes, however, that other "health care items and services" will be considered for the FY 2006 list. Device stakeholders have been monitoring the Agency for Healthcare Research & Quality closely to determine whether devices will be subject to cost-effectiveness research under the Medicare Modernization Act provision (2"The Gray Sheet" April 12, 2004, p. 10). Proposed research items must be received by May 7 and July 1 for the initial and FY 2006 lists, respectively...